Hepatitis crónica por virus C: evaluación de los pacientes tratados con antivirales de acción directa en el sistema público de Chile

Mezzano, Gabriel; Aguirre, Herman; Peña, Andrea; Gómez, Fernando; Nazal, Leyla; Arab, Juan Pablo; Roblero, Juan Pablo.
Rev. méd. Chile ; 149(12): 1687-1693, dic. 2021. graf, tab
Artículo en Español | LILACS-Express | ID: biblio-1424118

Documentos relacionados

  1. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
  2. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
  3. [Investigation of Hepatitis C Virus (HCV) Genotypes by "Reverse Hybridisation Strip Assay" and DNA Sequence Analysis Methods].
  4. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
  5. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
  6. Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
  7. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
  8. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
  9. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.
  10. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.